{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T07:29:57Z","timestamp":1789543797163,"version":"build-2803163510"},"reference-count":103,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.clml.2017.06.030","type":"journal-article","created":{"date-parts":[[2017,6,27]],"date-time":"2017-06-27T03:03:03Z","timestamp":1498532583000},"page":"545-554","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Monoclonal Antibodies in Multiple Myeloma: A New Wave of the Future"],"prefix":"10.1016","volume":"17","author":[{"given":"Daniel W.","family":"Sherbenou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomer M.","family":"Mark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Forsberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2017.06.030_bib1","first-page":"7","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clml.2017.06.030_bib2","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1182\/blood-2007-10-078022","article-title":"Multiple myeloma","volume":"111","author":"Kyle","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.030_bib3","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/bjh.13537","article-title":"Trends in survival of multiple myeloma patients in Germany and the United States in the first decade of the 21st century","volume":"171","author":"Pulte","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2017.06.030_bib4","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/leu.2011.196","article-title":"Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter International Myeloma Working Group study","volume":"26","author":"Kumar","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.06.030_bib5","doi-asserted-by":"crossref","first-page":"a002469","DOI":"10.1101\/cshperspect.a002469","article-title":"SLAM-family receptors: immune regulators with or without SAP-family adaptors","volume":"2","author":"Veillette","year":"2010","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.clml.2017.06.030_bib6","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1146\/annurev-immunol-030409-101302","article-title":"SLAM family receptors and SAP adaptors in immunity","volume":"29","author":"Cannons","year":"2011","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.clml.2017.06.030_bib7","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.imlet.2010.09.021","article-title":"Expression of SLAM (CD150) cell-surface receptors on human B-cell subsets: from pro-B to plasma cells","volume":"134","author":"De Salort","year":"2011","journal-title":"Immunol Lett"},{"key":"10.1016\/j.clml.2017.06.030_bib8","doi-asserted-by":"crossref","first-page":"5517","DOI":"10.4049\/jimmunol.167.10.5517","article-title":"Cutting edge: activation of NK cell-mediated cytotoxicity by a SAP-independent receptor of the CD2 family","volume":"167","author":"Bouchon","year":"2001","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.clml.2017.06.030_bib9","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/ni.1693","article-title":"Influence of CRACC, a SLAM family receptor coupled to the adaptor EAT-2, on natural killer cell function","volume":"10","author":"Cruz-Munoz","year":"2009","journal-title":"Nat Immunol"},{"key":"10.1016\/j.clml.2017.06.030_bib10","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1146\/annurev.immunol.25.022106.141651","article-title":"Regulation of cellular and humoral immune responses by the SLAM and SAP families of molecules","volume":"25","author":"Ma","year":"2007","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.clml.2017.06.030_bib11","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1128\/MCB.01107-14","article-title":"Immune cell inhibition by SLAMF7 is mediated by a mechanism requiring Src kinases, CD45, and SHIP-1 that is defective in multiple myeloma cells","volume":"35","author":"Guo","year":"2015","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.clml.2017.06.030_bib12","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1158\/1078-0432.CCR-07-4246","article-title":"CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma","volume":"14","author":"Hsi","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2017.06.030_bib13","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1182\/blood.V124.21.3431.3431","article-title":"Dissecting the mechanisms of activity of SLAMF7 and the targeting antibody elotuzumab in multiple myeloma","volume":"124","author":"Glavey","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.030_bib14","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1182\/blood-2007-08-107292","article-title":"Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu","volume":"112","author":"Tai","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.030_bib15","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1007\/s00262-013-1493-8","article-title":"Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC","volume":"62","author":"Collins","year":"2013","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.clml.2017.06.030_bib16","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00262-014-1610-3","article-title":"Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-\u03b1 pathways","volume":"64","author":"Balasa","year":"2015","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.clml.2017.06.030_bib17","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1158\/1535-7163.MCT-09-0483","article-title":"Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma","volume":"8","author":"van Rhee","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.clml.2017.06.030_bib18","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1182\/blood-2011-06-360552","article-title":"A\u00a0phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma","volume":"120","author":"Zonder","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.030_bib19","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.06.030_bib20","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1182\/blood-2016-01-694604","article-title":"Randomized phase 2 study of elotuzumab plus bortezomib\/dexamethasone (Bd) versus Bd for relapsed\/refractory multiple myeloma","volume":"127","author":"Jakubowiak","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.030_bib21","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with daratumumab monotherapy in multiple myeloma","volume":"373","author":"Lokhorst","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.06.030_bib22","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","article-title":"Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial","volume":"387","author":"Lonial","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2017.06.030_bib23","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.06.030_bib24","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.06.030_bib25","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood.V126.23.28.28","article-title":"ELOQUENT-2 update: a phase 3, randomized, open-label study of elotuzumab in combination with lenalidomide\/dexamethasone in patients with relapsed\/refractory multiple myeloma \u20143-year safety and efficacy follow-up","volume":"126","author":"Dimopoulos","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.030_bib26","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1182\/blood.V99.3.754","article-title":"Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fc\u03b3RIIIa gene","volume":"99","author":"Cartron","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.030_bib27","doi-asserted-by":"crossref","first-page":"6591","DOI":"10.1074\/jbc.M009483200","article-title":"High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R","volume":"276","author":"Shields","year":"2001","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.clml.2017.06.030_bib28","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1200\/JCO.2003.05.013","article-title":"Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma","volume":"21","author":"Weng","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"issue":"4 suppl 5","key":"10.1016\/j.clml.2017.06.030_bib29","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1053\/j.seminoncol.2005.06.018","article-title":"IMiDs: a novel class of immunomodulators","volume":"32","author":"Knight","year":"2005","journal-title":"Semin Oncol"},{"key":"10.1016\/j.clml.2017.06.030_bib30","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1007\/s00262-008-0512-7","article-title":"Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation","volume":"57","author":"Zhu","year":"2008","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.clml.2017.06.030_bib31","doi-asserted-by":"crossref","first-page":"163","DOI":"10.4049\/jimmunol.180.1.163","article-title":"Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition","volume":"180","author":"Hallett","year":"2008","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.clml.2017.06.030_bib32","doi-asserted-by":"crossref","first-page":"6120","DOI":"10.1182\/blood-2008-11-190421","article-title":"Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells","volume":"113","author":"Lundqvist","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.030_bib33","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1016\/j.molimm.2010.05.003","article-title":"The proteasome inhibitor bortezomib disrupts tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression and natural killer (NK) cell killing of TRAIL receptor-positive multiple myeloma cells","volume":"47","author":"Feng","year":"2010","journal-title":"Mol Immunol"},{"key":"10.1016\/j.clml.2017.06.030_bib34","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1182\/blood.V92.4.1324","article-title":"Mice deficient for the ecto-nicotinamide adenine dinucleotide glycohydrolase CD38 exhibit altered humoral immune responses","volume":"92","author":"Cockayne","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.030_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0145-2126(00)00093-X","article-title":"Human CD38: a (r)evolutionary story of enzymes and receptors","volume":"25","author":"Deaglio","year":"2001","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2017.06.030_bib36","doi-asserted-by":"crossref","first-page":"395","DOI":"10.4049\/jimmunol.160.1.395","article-title":"Human CD38 (ADP-ribosyl cyclase) is a counter-receptor of CD31, an Ig superfamily member","volume":"160","author":"Deaglio","year":"1998","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.clml.2017.06.030_bib37","doi-asserted-by":"crossref","first-page":"952","DOI":"10.4049\/jimmunol.153.3.952","article-title":"Interaction between endothelium and CD4+CD45RA+ lymphocytes: role of the human CD38 molecule","volume":"153","author":"Dianzani","year":"1994","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.clml.2017.06.030_bib38","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1126\/science.8235624","article-title":"Formation and hydrolysis of cyclic ADP-ribose catalyzed by lymphocyte antigen CD38","volume":"262","author":"Howard","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.clml.2017.06.030_bib39","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/0167-5699(94)90148-1","article-title":"Human CD38: a glycoprotein in search of a function","volume":"15","author":"Malavasi","year":"1994","journal-title":"Immunol Today"},{"key":"10.1016\/j.clml.2017.06.030_bib40","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1073\/pnas.77.3.1588","article-title":"Discrete stages of human intrathymic differentiation: analysis of normal thymocytes and leukemic lymphoblasts of T-cell lineage","volume":"77","author":"Reinherz","year":"1980","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clml.2017.06.030_bib41","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/BF01697400","article-title":"Multiparameter analyses of normal and malignant human plasma cells: CD38++, CD56+, CD54+, cIg+ is the common phenotype of myeloma cells","volume":"64","author":"Leo","year":"1992","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2017.06.030_bib42","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1182\/blood.V84.9.3017.3017","article-title":"Anti-CD38-blocked ricin: an immunotoxin for the treatment of multiple myeloma","volume":"84","author":"Goldmacher","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.030_bib43","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1182\/blood.V77.5.1071.1071","article-title":"Preliminary studies for an immunotherapeutic approach to the treatment of human myeloma using chimeric anti-CD38 antibody","volume":"77","author":"Stevenson","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.030_bib44","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors","volume":"186","author":"de Weers","year":"2011","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.clml.2017.06.030_bib45","doi-asserted-by":"crossref","first-page":"807","DOI":"10.4049\/jimmunol.1501351","article-title":"The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via Fc\u03b3 receptor-mediated cross-linking","volume":"197","author":"Overdijk","year":"2016","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.clml.2017.06.030_bib46","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/19420862.2015.1007813","article-title":"Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma","volume":"7","author":"Overdijk","year":"2015","journal-title":"MAbs"},{"key":"10.1016\/j.clml.2017.06.030_bib47","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1182\/blood.V124.21.3474.3474","article-title":"Direct in\u00a0vitro comparison of daratumumab with surrogate analogs of CD38 antibodies MOR03087, SAR650984 and Ab79","volume":"124","author":"Lammerts van Bueren","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.030_bib48","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1158\/1078-0432.CCR-14-1813","article-title":"Preclinical evidence for the therapeutic potential of CD38-targeted immuno-chemotherapy in multiple myeloma patients refractory to lenalidomide and bortezomib","volume":"21","author":"Nijhof","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2017.06.030_bib49","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3324\/haematol.2010.030759","article-title":"Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab","volume":"96","author":"van der Veer","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2017.06.030_bib50","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s40265-015-0536-1","article-title":"Daratumumab: first global approval","volume":"76","author":"McKeage","year":"2016","journal-title":"Drugs"},{"issue":"15 suppl","key":"10.1016\/j.clml.2017.06.030_bib51","doi-asserted-by":"crossref","first-page":"CT320","DOI":"10.1158\/1538-7445.AM2015-CT320","article-title":"Abstract CT320: an open-label, multicenter, phase Ib study of daratumumab in combination with backbone regimens in patients with multiple myeloma","volume":"75","author":"Comenzo","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2017.06.030_bib52","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1182\/blood-2016-07-726729","article-title":"Phase 1\/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"128","author":"Plesner","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.030_bib53","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1182\/blood.V128.22.2142.2142","article-title":"Use of montelukast to reduce infusion reactions in an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma","volume":"128","author":"Chari","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.030_bib54","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.1149.1149","article-title":"Open-label, multicenter, dose escalation phase 1b study to assess the subcutaneous delivery of daratumumab in patients (pts) with relapsed or refractory multiple myeloma (PAVO)","volume":"128","author":"Usmani","year":"2016","journal-title":"Blood"},{"issue":"6 Pt 2","key":"10.1016\/j.clml.2017.06.030_bib55","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1111\/trf.13150","article-title":"When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy","volume":"55","author":"Oostendorp","year":"2015","journal-title":"Transfusion"},{"key":"10.1016\/j.clml.2017.06.030_bib56","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1111\/trf.13789","article-title":"International validation of a dithiothreitol (DTT)-based method to resolve the daratumumab interference with blood compatibility testing","volume":"56","author":"Chapuy","year":"2016","journal-title":"Transfusion"},{"issue":"6 Pt 2","key":"10.1016\/j.clml.2017.06.030_bib57","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1111\/trf.13069","article-title":"Resolving the daratumumab interference with blood compatibility testing","volume":"55","author":"Chapuy","year":"2015","journal-title":"Transfusion"},{"key":"10.1016\/j.clml.2017.06.030_bib58","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1515\/cclm-2015-0888","article-title":"Interference of daratumumab in monitoring multiple myeloma patients using serum immunofixation electrophoresis can be abrogated using the daratumumab IFE reflex assay (DIRA)","volume":"54","author":"van de Donk","year":"2016","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.clml.2017.06.030_bib59","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1515\/cclm-2015-1031","article-title":"Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference","volume":"54","author":"McCudden","year":"2016","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.clml.2017.06.030_bib60","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.blre.2014.09.011","article-title":"The development of potential antibody-based therapies for myeloma","volume":"29","author":"Sherbenou","year":"2015","journal-title":"Blood Rev"},{"issue":"3 suppl","key":"10.1016\/j.clml.2017.06.030_bib61","first-page":"814s","article-title":"Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors","volume":"50","author":"Jain","year":"1990","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2017.06.030_bib62","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1208\/s12248-009-9157-5","article-title":"Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease","volume":"12","author":"Tabrizi","year":"2010","journal-title":"AAPS J"},{"key":"10.1016\/j.clml.2017.06.030_bib63","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1182\/blood.V126.23.505.505","article-title":"Pembrolizumab in combination with lenalidomide and low-dose dexamethasone for relapsed\/refractory multiple myeloma (RRMM): Keynote-023","volume":"126","author":"San Miguel","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.030_bib64","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1182\/blood.V126.23.506.506","article-title":"A\u00a0phase II study of anti PD-1 antibody pembrolizumab, pomalidomide and dexamethasone in patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"128","author":"Badros","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.030_bib65","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1182\/blood.V128.22.2119.2119","article-title":"Pembrolizumab in combination with pomalidomide and dexamethasone (PEMBRO\/POM\/DEX) for pomalidomide exposed relapsed or refractory multiple myeloma","volume":"128","author":"Wilson","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.030_bib66","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1182\/blood.V128.22.1148.1148","volume":"128","author":"Cohen","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.030_bib67","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1182\/blood.V118.21.305.305","article-title":"BT062, an antibody-drug conjugate directed against CD138, shows clinical activity in patients with relapsed or relapsed\/refractory multiple myeloma","volume":"118","author":"Jagannath","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.030_bib68","doi-asserted-by":"crossref","first-page":"4486","DOI":"10.1182\/blood.V128.22.4486.4486","article-title":"Indatuximab ravtansine (BT062) in combination with low-dose dexamethasone and lenalidomide or pomalidomide: clinical activity in patients with relapsed\/refractory multiple myeloma","volume":"128","author":"Kelly","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.030_bib69","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1182\/blood.V128.22.383.383","article-title":"Preclinical evaluation of a potent anti-BCMA CD3 bispecific molecule for the treatment of multiple myeloma","volume":"128","author":"Panowski","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.030_bib70","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.117.117","article-title":"Target expression, preclinical activity and mechanism of action of EM801: a novel first-in-class BCMA T-cell bispecific antibody for the treatment of multiple myeloma","volume":"126","author":"Seckinger","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.030_bib71","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1182\/blood.V128.22.2096.2096","article-title":"New insights into the mechanism of action (MoA) of first-in-class IgG-based BCMA T-cell bispecific antibody (TCB) for the treatment of multiple myeloma (MM)","volume":"128","author":"Moreno","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.030_bib72","doi-asserted-by":"crossref","first-page":"4475","DOI":"10.1182\/blood.V128.22.4475.4475","article-title":"Anti-FcRH5\/CD3 T cell dependent bispecific antibody (TDB) for the treatment of multiple myeloma","volume":"128","author":"Li","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.030_bib73","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/cas.12631","article-title":"Immunotherapy based on bispecific T-cell engager with hIgG1 Fc sequence as a new therapeutic strategy in multiple myeloma","volume":"106","author":"Zou","year":"2015","journal-title":"Cancer Sci"},{"key":"10.1016\/j.clml.2017.06.030_bib74","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","article-title":"T\u00a0cells expressing an anti\u2013B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma","volume":"128","author":"Ali","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.030_bib75","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1182\/blood.V128.22.1147.1147","article-title":"B-cell maturation antigen (BCMA)-specific chimeric antigen receptor T cells (CART-BCMA) for multiple myeloma (MM): initial safety and efficacy from a phase I study","volume":"128","author":"Cohen","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.030_bib76","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1056\/NEJMoa1504542","article-title":"Chimeric antigen receptor T cells against CD19 for multiple myeloma","volume":"373","author":"Garfall","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.06.030_bib77","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2006-10-051482","article-title":"Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-\u03b3 and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway","volume":"110","author":"Liu","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.030_bib78","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1182\/blood-2010-02-271874","article-title":"The PD-1\/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti\u2013PD-1 antibody","volume":"116","author":"Benson","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.030_bib79","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.bbmt.2011.03.011","article-title":"Immunosuppressive effects of multiple myeloma are overcome by PD-L1 blockade","volume":"17","author":"Hallett","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2017.06.030_bib80","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/leu.2012.213","article-title":"Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma","volume":"27","author":"Tamura","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.06.030_bib81","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1038\/bcj.2015.7","article-title":"Immunomodulatory molecule PD-L1 is expressed on malignant plasma cells and myeloma-propagating pre-plasma cells in the bone marrow of multiple myeloma patients","volume":"5","author":"Yousef","year":"2015","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2017.06.030_bib82","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1038\/leu.2015.11","article-title":"Targeting PD1-PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells","volume":"29","author":"Ray","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.06.030_bib83","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.06.030_bib84","doi-asserted-by":"crossref","first-page":"4607","DOI":"10.1158\/1078-0432.CCR-15-0200","article-title":"Lenalidomide enhances immune checkpoint blockade induced immune response in multiple myeloma","volume":"21","author":"Gorgun","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2017.06.030_bib85","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2016-08-731885","article-title":"Targeting the PD-1\/PD-L1 axis in multiple myeloma: a dream or a reality?","volume":"129","author":"Rosenblatt","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.030_bib86","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/leu.2013.310","article-title":"Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma","volume":"28","author":"Atanackovic","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.06.030_bib87","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.06.030_bib88","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.06.030_bib89","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1039\/c3np20113a","article-title":"The antibody-drug conjugate: an enabling modality for natural product-based cancer therapeutics","volume":"30","author":"Gerber","year":"2013","journal-title":"Nat Prod Rep"},{"key":"10.1016\/j.clml.2017.06.030_bib90","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1146\/annurev-med-050311-201823","article-title":"Antibody-drug conjugates in cancer therapy","volume":"64","author":"Sievers","year":"2013","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.clml.2017.06.030_bib91","doi-asserted-by":"crossref","first-page":"4028","DOI":"10.1158\/1078-0432.CCR-08-2867","article-title":"The monoclonal antibody nBT062 conjugated to cytotoxic maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in\u00a0vitro and in\u00a0vivo","volume":"15","author":"Ikeda","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2017.06.030_bib92","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1182\/blood-2013-10-535088","article-title":"Novel anti\u2013B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma","volume":"123","author":"Tai","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.030_bib93","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13045-016-0380-0","article-title":"Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies","volume":"10","author":"Sch\u00f6nfeld","year":"2017","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.clml.2017.06.030_bib94","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1158\/1535-7163.MCT-12-0087","article-title":"FcRL5 as a target of antibody-drug conjugates for the treatment of multiple myeloma","volume":"11","author":"Elkins","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.clml.2017.06.030_bib95","doi-asserted-by":"crossref","first-page":"4640","DOI":"10.1172\/JCI85856","article-title":"Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells","volume":"126","author":"Sherbenou","year":"2016","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.clml.2017.06.030_bib96","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2017.06.030_bib97","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/nrd4478","article-title":"Bispecific antibodies rise again","volume":"13","author":"Garber","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.clml.2017.06.030_bib98","first-page":"38","article-title":"Fc engineering for developing therapeutic bispecific antibodies and novel scaffolds","volume":"8","author":"Liu","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.clml.2017.06.030_bib99","doi-asserted-by":"crossref","first-page":"5288","DOI":"10.1021\/jacs.5b01876","article-title":"An anti-B cell maturation antigen bispecific antibody for multiple myeloma","volume":"137","author":"Ramadoss","year":"2015","journal-title":"J\u00a0Am Chem Soc"},{"key":"10.1016\/j.clml.2017.06.030_bib100","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1182\/blood-2016-01-694356","article-title":"Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy","volume":"128","author":"Bhoj","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.030_bib101","doi-asserted-by":"crossref","first-page":"616","DOI":"10.3324\/haematol.2015.137620","article-title":"Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma","volume":"101","author":"Drent","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2017.06.030_bib102","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jocit.2014.11.001","article-title":"CD138-directed adoptive immunotherapy of chimeric antigen receptor (CAR)-modified T cells for multiple myeloma","volume":"2","author":"Guo","year":"2016","journal-title":"J\u00a0Cell Immunother"},{"key":"10.1016\/j.clml.2017.06.030_bib103","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1182\/blood-2016-03-703439","article-title":"CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma","volume":"128","author":"Nijhof","year":"2016","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226501730277X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226501730277X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:29:22Z","timestamp":1761870562000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S215226501730277X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":103,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S215226501730277X"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2017.06.030","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Monoclonal Antibodies in Multiple Myeloma: A New Wave of the Future","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2017.06.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}